Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 5/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 7/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | PRKACA | P17612 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165263 | 0.72 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL2000322 | 0.69 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL29072533 | 0.68 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBRET | |
| SCHEMBL5239193 | 0.67 | CCR1 (0.50) | PIM1PIM3ALDH1A1MAPT | |
| SCHEMBL6163883 | 0.67 | NOS3 (0.41) | MAP4K4ROCK1 | |
| SCHEMBL478773 | 0.65 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBRET | |
| SCHEMBL4317878 | 0.62 | LIMK1 (0.47) | PI4KAPI4K2BPI4K2API4KBRET | |
| SCHEMBL6161689 | 0.61 | DYRK1A (0.31) | DYRK1A | |
| SCHEMBL6104655 | 0.58 | ALDH1A1 (0.41) | KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL31057909 | 0.58 | LIMK1 (0.39) | PI4KAPI4K2BPI4K2API4KBPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991638-B1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | claimed |
| US-6906070-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | claimed |
| EP-1175419-B1 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-28 | — | — | EP | claimed |
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | WEXLER RUTH R (US) | 2003-03-13 | — | — | US | claimed |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | claimed |
| EP-1175419-A2 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2000059902-A2 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | claimed |
| EP-0991638-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1998057951-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0991638-B1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6906070-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-6689770-B2 | AN INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES, AS ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| EP-1175419-B1 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | WEXLER RUTH R (US) | 2003-03-13 | — | — | US | disclosed |
| US-6399644-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2002-06-04 | — | — | US | disclosed |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
| US-6339099-B1 | FOR THERAPY AND PROPHYLAXIS OF THROMBOEMBOLIC DISORDER | DUPONT PHARMACEUTICALS COMPANY | 2002-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | F12, F11, TFPI | PI4KA 4139/4885PI4K2B 4180/4885PI4K2A 4393/4885 |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | F11, SERPINC1, TFPI | PI4KA 3109/4885PI4K2B 3128/4885PI4K2A 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.